Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Myeloma: early-phase trial registry
167 of 441 indexed Multiple Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #11 of 28,963 conditions by registered trial count.
441 US clinical trials · 167 currently recruiting · #11 of 28,963 conditions by registered trial count
Multiple Myeloma: 441 US clinical trials tracked, 167 recruiting.
Multiple Myeloma is the subject of 441 registered US clinical trials on ClinicalTrials.gov, 167 of them currently open to new participants. 52 are in Phase 3-4 (later-stage) and 298 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 34 of these trials.
Open enrollment, early-phase tilt
Multiple Myeloma has 441 registered US clinical trials, 167 of them open to new participants right now, about 38% of the total.
- 167
- recruiting participants now
- 38%
- of trials open to enrollment
- 52
- in Phase 3-4 (later-stage)
- 34
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #11 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Multiple Myeloma on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Myeloma recruits in line with its size-band peers.
167 of 441 indexed trials (37.9%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Multiple Myeloma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 34 of 441 trials (7.7%). 154 distinct sponsors appear on at least one study for this condition label.
-
Typical Multiple Myeloma enrolment sits around 65 participants.
Median target enrolment is 65 among the 439 trials that report a genuine target (sentinel values excluded). 262 of those (59.7%) plan for fewer than 100 participants.
-
Multiple Myeloma research is mostly interventional.
386 interventional and 55 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
441 total, page 1 of 9
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Dana-Farber Cancer Institute
NCT03689595
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Boston Medical Center
NCT00898235
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
University of Alabama at Birmingham
NCT05556928
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Ohio State University Comprehensive Cancer Center
NCT01408225
Collection of Tissue Samples for Cancer Research
National Cancer Institute (NCI)
NCT00900198
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
American Society of Clinical Oncology
NCT02693535
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
University of California, Davis
NCT04314752
Family Study of Lymphoproliferative Disorders
Mayo Clinic
NCT00626496
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Wake Forest University Health Sciences
NCT01890486
Registry for Adults With Plasma Cell Disorders (PCD's)
UNC Lineberger Comprehensive Cancer Center
NCT03717844
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
Wake Forest University Health Sciences
NCT06644625
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
European Myeloma Network B.V.
NCT05243797
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Janssen Research & Development
NCT05552222
Tissue Collection for Studies of Lymph Cancer
National Cancer Institute (NCI)
NCT01676805
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Bristol-Myers Squibb
NCT05827016
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
University of Miami
NCT05361694
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Washington University School of Medicine
NCT06340646
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Pfizer
NCT05020236
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Janssen Research & Development
NCT06208150
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
City of Hope Medical Center
NCT07225738
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie
NCT07095452
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Center for International Blood and Marrow Transplant Research
NCT03127761
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
GlaxoSmithKline
NCT06679101
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Memorial Sloan Kettering Cancer Center
NCT00582621
A Study of Daratumumab
Janssen Research & Development
NCT05438043
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
National Cancer Institute (NCI)
NCT02682667
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Medical College of Wisconsin
NCT03375619
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
UNC Lineberger Comprehensive Cancer Center
NCT06296368
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
NCT06152575
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
Brigham and Women's Hospital
NCT06483139
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
All4Cure
NCT06149910
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Kite, A Gilead Company
NCT06413498
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
AbbVie
NCT06892522
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development
NCT07258511
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Regeneron Pharmaceuticals
NCT03761108
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
NCT06158841
Mosaic Trial for Stem Cell Transplant Recipients
Northwestern University
NCT06960993
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Regeneron Pharmaceuticals
NCT05137054
Pre-malignant States to Hematologic Malignancies in Firefighters
Wake Forest University Health Sciences
NCT06870760
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Karyopharm Therapeutics
NCT02343042
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
University of Alabama at Birmingham
NCT05231629
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Janssen Research & Development
NCT05201781
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Cancer Institute (NCI)
NCT03412877
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Poseida Therapeutics
NCT04960579
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb
NCT05372354
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric
NCT04068597
Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
Washington University School of Medicine
NCT06910670
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT06297226
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
AstraZeneca
NCT06106945
A Dietary Study for People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT07226609
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 142 |
| Phase 3 | 45 |
| Phase 4 | 7 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Multiple Myeloma right now
167 recruiting of 441 indexed (38% open).
Phase mix: 52 late (III/IV) vs 298 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (34 trials), 9 others listed. 50 shown below, recruiting first. #11 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Multiple Myeloma?
PlainTrial tracks 441 US clinical trials for Multiple Myeloma, of which 167 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Multiple Myeloma?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.